November 27th 2024
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.
November 25th 2024
November 15th 2024
November 14th 2024
November 12th 2024
FDA Updates Prescribing Label for Ibrutinib for Waldenström Macroglobulinemia Indication
December 23rd 2020The FDA updated the prescribing label for the approval of ibrutinib to include efficacy and safety data as combination therapy with rituximab as treatment of patients with Waldenström’s macroglobulinemia.
Read More
CD123-Targeting ADC IMGN632 Demonstrates Encouraging Findings in Rare Blood Cancer
December 23rd 2020The novel CD123-targeting antibody-drug conjugate IMGN632 demonstrated promising clinical activity in a cohort of heavily pretreated patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm and had a favorable tolerability.
Read More
Treating Transplant-Ineligible MM: Implications of the PEGASUS Study
December 23rd 2020Hematologist Rafael Fonseca comments on data demonstrated by the PEGASUS study in transplant-ineligible multiple myeloma and expectations for treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone vs other options moving forward.
Watch
First-Line Treatment Options and Subsequent Risks Facing Multiple Myeloma Patients
December 22nd 2020Saad Usmani, MD, discusses what first-line options are available for patients with multiple myeloma while highlighting the difficulties in defining high-risk characteristics associated with multiple myeloma.
Watch